All In Biotech

Investigational drug · Phase 2

HA131

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Hepatocellular Carcinoma (HCC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "HA131"

First trial start

2025

Dec 23, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HA131", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Hepatocellular Carcinoma (HCC)

Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "HA131" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Hepatocellular Carcinoma (HCC)

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • PD-1 inhibitorPhase 38 trials

    BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)

  • AK105Phase 31 trial

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)

  • B7-H3 CAR-NKEB-G3B7-NK dual-target CAR-NK cells, Dual-target GPC3Phase 22 trials

    Beijing Biotech · Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Relapsed Neuroblastoma

  • WGI-0301Phase 22 trials

    Zhejiang Haichang Biotech Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC), Hepato Cellular Carcinoma (HCC), Renal Cell Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.